Provided by Tiger Trade Technology Pte. Ltd.

Black Diamond Therapeutics, Inc.

2.33
+0.03001.30%
Post-market: 2.330.00000.00%16:10 EST
Volume:482.28K
Turnover:1.11M
Market Cap:132.75M
PE:6.17
High:2.34
Open:2.28
Low:2.24
Close:2.30
52wk High:4.94
52wk Low:1.20
Shares:56.97M
Float Shares:39.24M
Volume Ratio:1.24
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3779
EPS(LYR):-1.2662
ROE:19.23%
ROA:6.26%
PB:1.05
PE(LYR):-1.84

Loading ...

Black Diamond Therapeutics price target lowered to $8 from $9 at Piper Sandler

TIPRANKS
·
Jan 16

Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Simply Wall St.
·
Jan 10

Black Diamond Advances Silevertinib Combo Into Phase 2 for Hard‑to‑Treat Brain Cancer

TIPRANKS
·
Jan 09

BUZZ-U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox

Reuters
·
Dec 04, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics

Reuters
·
Dec 03, 2025

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM

Reuters
·
Dec 03, 2025

BUZZ-Black Diamond rises as lung cancer drug meets main goal

Reuters
·
Dec 03, 2025

Black Diamond: to Initiate Randomized Phase 2 Trial of Silevertinib in Newly Diagnosed GBM Patients in 1H 2026; Initial Data Anticipated in 2028

THOMSON REUTERS
·
Dec 03, 2025

Black Diamond Therapeutics Inc - Silevertinib Shows 60% Orr and 86% CNS Response in 1L Nsclc

THOMSON REUTERS
·
Dec 03, 2025

Black Diamond Therapeutics Inc: Pfs Data for 1L Nsclc Patients Expected in Q2 2026

THOMSON REUTERS
·
Dec 03, 2025

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

GlobeNewswire
·
Dec 03, 2025

Black Diamond Therapeutics Announces Phase 2 Silevertinib Clinical Trial Results

Reuters
·
Dec 03, 2025

Black Diamond Therapeutics Files For Mixed Shelf Of Up To $500 Million - SEC Filing

Reuters
·
Nov 20, 2025

U.S. RESEARCH ROUNDUP- Autodesk, Crowdstrike, Zscaler

Reuters
·
Nov 18, 2025

Black Diamond Therapeutics Inc : Piper Sandler Assumes Coverage With Overweight Rating; Target Price $9

THOMSON REUTERS
·
Nov 18, 2025

Black Diamond Therapeutics assumed with an Overweight at Piper Sandler

TIPRANKS
·
Nov 18, 2025

BRIEF-Black Diamond Therapeutics Files For Mixed Shelf Of Up To $500 Million - SEC Filing

Reuters
·
Nov 14, 2025

Stifel Nicolaus Reaffirms Their Buy Rating on Black Diamond Therapeutics (BDTX)

TIPRANKS
·
Nov 13, 2025

Black Diamond Therapeutics Reports Positive Financial Turnaround

TIPRANKS
·
Nov 11, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 10, 2025